|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Sanofi-Aventis |
| Information provided by: | Sanofi-Aventis |
| ClinicalTrials.gov Identifier: | NCT00029822 |
Purpose
A study to determine the effect on prevention of Acute Urinary Retention (inability to urinate) in males with an enlarged prostate, also known as BPH.
| Condition | Intervention | Phase |
|
Urinary Retention Prostatic Hyperplasia Benign Prostatic Hypertrophy |
Drug: Alfuzosin (SL770499) |
Phase III |
| Drug Information available for: | Alfuzosin Alfuzosin hydrochloride |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Long-Term, Efficacy and Safety of Alfuzosin 10 MG OD on the Risk of Acute Urinary Retention and the Need for Surgery in Patients With BPH. A Two Year, Randomized, Multicenter, Double-Blind, Parallel Group, Placebo-Controlled Study. |
Eligibility
| Ages Eligible for Study: | 55 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Contacts and Locations![]() |
Show 54 Study Locations |
| Sanofi-Aventis |
| Study Director: | ICD CSD | Sanofi-Aventis |
More Information
Related Info 
  |
Related Info 
  |
| Responsible Party: | sanofi-aventis ( ICD Study Director ) |
| Study ID Numbers: | EFC4485, SL770499 |
| First Received: | January 23, 2002 |
| Last Updated: | June 6, 2008 |
| ClinicalTrials.gov Identifier: | NCT00029822 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|